Study protocol for a randomized, double-blind, double-simulation, positive drug-parallel controlled trial investigating the impact of modified Linggui Yinchen decoction on ApoA1/LCAT activity in the treatment of obese MAFLD
Open Access
- 5 February 2026
- journal article
- Published by Wolters Kluwer Health in Guidelines and Standards of Chinese Medicine
- Vol. 4 (1) , 63-71
Abstract
Objective: Metabolic-associated fatty liver disease (MAFLD), formerly known as non-alcoholic fatty liver disease (NAFLD), was renamed in 2020 to emphasize its metabolic nature. Presently, modern medicine faces challenges in providing effective treatments for MAFLD. In contrast, traditional Chinese medicine (TCM) has demonstrated potential in alleviating clinical symptoms and improving liver function. Modified Linggui Yinchen Decoction (M-LGYCD) is derived from Lingguizhugan and Yinchenhao decoctions. This blend is specifically designed to invigorate the spleen, soothe the liver, and alleviate the stagnation of turbid yin. Methods: This study develops a randomized, double-blind, positive drug-controlled trial protocol to investigate the effects of M-LGYCD on apolipoprotein A1 (ApoA1)/lecithin cholesterol acyltransferase (LCAT) activity in reverse cholesterol transport. It is planned to recruit 124 outpatient and inpatient obese MAFLD patients with syndrome of spleen deficiency and liver depression, along with turbid yin stagnation, for a period of 8 weeks. The research goal is to assess the efficiency and safety of M-LGYCD by analyzing liver and kidney functions, blood lipids, metabolic indicators, and patient-reported symptoms before and after treatment. In addition, plasma ApoA1/LCAT activity measurement, transcriptome analysis, and lipid metabolome analysis will be conducted to elucidate the therapeutic mechanism of M-LGYCD and reveal the connotation of spleen deficiency and liver depression, along with turbid yin stagnation syndrome. Discussion: This study is expected to provide a scientific basis and new therapeutic ideas for the TCM treatment of obese MAFLD.Keywords
This publication has 28 references indexed in Scilit:
- A multisociety Delphi consensus statement on new fatty liver disease nomenclatureAnnals of Hepatology, 2023
- Lipid Disorders and Metabolic-Associated Fatty Liver DiseaseEndocrinology and Metabolism Clinics of North America, 2023
- Yinchenhao Tang alleviates high fat diet induced NAFLD by increasing NR1H4 and APOA1 expressionJournal of Traditional and Complementary Medicine, 2023
- Effects of lifestyle intervention on IGF-1, IGFBP-3, and insulin resistance in children with obesity with or without metabolic-associated fatty liver diseaseEuropean Journal of Pediatrics, 2022
- Lingguizhugan Decoction, a Chinese herbal formula, improves insulin resistance in overweight/obese subjects with non-alcoholic fatty liver disease: a translational approachFrontiers of Medicine, 2022
- HDL maturation and remodellingBiochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids, 2022
- Function of the endolysosomal network in cholesterol homeostasis and metabolic-associated fatty liver disease (MAFLD)Molecular Metabolism, 2021
- Dysregulated lipid metabolism links NAFLD to cardiovascular diseaseMolecular Metabolism, 2020
- A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statementJournal of Hepatology, 2020
- Loss of LCAT activity in the golden Syrian hamster elicits pro-atherogenic dyslipidemia and enhanced atherosclerosisMetabolism, 2018